Dermatology

Economists Probe Cost-Effectiveness of Biosimilars

January 7, 2021

Tony Hagen

Article

Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.

Romiplostim Biosimilar Study Demonstrates Safety, Efficacy in Real-World India Population

December 8, 2020

Tony Hagen

Article

A high overall response rate of 93% was observed for patients with immune thrombocytopenic purpura who received romiplostim biosimilar.

Newly Created Viatris Joins the Biosimilars Forum

November 30, 2020

Tony Hagen

Article

The merger of Pfizer's Upjohn division and Mylan has created a biosimilars powerhouse with global reach.

Providers Exploit Minor Differences Between Innovator Drugs and Biosimilars

November 24, 2020

Skylar Jeremias

Article

Minute differences between biosimilars and reference products are not considered “clinically meaningful,” but these differences are exploitable when it comes to addressing allergies related to originator products.

Opinion: Embrace the Era of Next-Generation Biologics

November 21, 2020

Bincy P. Abraham, MD

Article

Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them.

High Patient Retention Observed for Multiple Etanercept Switches

November 16, 2020

Tony Hagen

Article

Investigators said their study is valuable because biosimilar switching is likely to increase for economic reasons.

IGBA Launches Global Biosimilars Week

November 16, 2020

Tony Hagen

Article

The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars.

High Adherence Noted Among Infliximab Biosimilar Users

November 16, 2020

Tony Hagen

Article

Investigators looked at adherence in patients who switched from reference infliximab during treatment for rheumatologic and gastrointestinal treatment.

Study: Specialty Drug Spending Net of Rebates Soars for Private Insurance, Medicare Part D

November 2, 2020

Deana Ferreri, PhD

Article

This study of specialty drug spending looks beyond rebates to evaluate growth in spending from 2010 to 2017.

Ten Reasons Why Biosimilar Candidates Should Not Be Tested for Clinical Efficacy

October 31, 2020

Sarfaraz K. Niazi, PhD

Article

The FDA may require comparative clinical efficacy for biosimilar approval, but on top of all the other required and available evidence, these trials add little value, Sarfaraz K. Niazi, PhD, states.

x